Manikwar, PrakashBüyüktimkin, BarlasKiptoo, PaulBadawi, Ahmed H.Galeva, Nadezhda A.Williams, Todd D.Siahaan, Teruna J.2017-04-282017-04-282012-03-21Manikwar, P., Büyüktimkin, B., Kiptoo, P., Badawi, A. H., Galeva, N. A., Williams, T. D., & Siahaan, T. J. (2012). I-Domain-Antigen Conjugate (IDAC) for Delivering Antigenic Peptides to APC: Synthesis, Characterization, and in vivo EAE Suppression. Bioconjugate Chemistry, 23(3), 509–517. http://doi.org/10.1021/bc200580jhttps://hdl.handle.net/1808/23855The objectives of this work are to characterize the identity of I-domain-antigen conjugate (IDAC) and to evaluate the in vivo efficacy of IDAC in suppressing experimental autoimmune encephalomyelitis (EAE) in mouse model. The hypothesis is that the I-domain delivers PLP139-151 peptides to antigen-presenting cells (APC) and alters the immune system by simultaneously binding to ICAM-1 and MHC-II, blocking immunological synapse formation. IDAC was synthesized by derivatizing the lysine residues with maleimide groups followed by conjugation with PLP-Cys-OH peptide. Conjugation with PLP peptide does not alter the secondary structure of the protein as determined by CD. IDAC suppresses the progression of EAE while I-domain and GMB-I-domain could only delay the onset of EAE. As a positive control, Ac-PLP-BPI-NH2-2 can effectively suppress the progress of EAE. The number of conjugation sites and the sites of conjugations in IDAC were determined using tryptic digest followed by LC-MS analysis. In conclusion, conjugation of I-domain with an antigenic peptide (PLP) resulted in an active molecule to suppress EAE in vivo.Copyright © 2012 American Chemical SocietyArticle10.1021/bc200580jPMC3311109openAccess